(PubMed) Rinella ME, Lazarus JV, Ratziu V, et al
%20deficiency%3F)
64889-81-2 Chemical Name: Glutathione-S-acetaminophen conjugate Synonyms Aa-gsh;Aa-glutathion;3-Gsh-acetaminophen;Acetaminophen glutathion;Acetaminophen Impurity 37;3-(glutathion-S-yl)acetaminophen;Acetaminophen glutathione conjugate;3-GlutathionylacetaMinophen DisodiuM;Glutathione-S-acetaminophen conjugate;Acetaminophen Glutathione Disodium Salt CBNumber: CB01247918 Molecular Formula: C18H24N4O8S Molecular Weight: 456.47 MDL Number: MOL File: 64889-81-2.mol MSDS File: SDS TDS File: TDS Last updated:2026-04-24 14:59:10 Glutathione-S-acetaminophen conjugate price More Price(14) Glutathione-S-acetaminophen conjugate Preparation Products And Raw materials Raw materials Preparation Products 64889-81-2(Glutathione-S-acetaminophen conjugate)Related Search: GLUTATHIONE S-TRANSFERASE Disodium edetate dihydrate Glutathione (reduced) sodium salt 1-FMOC-PIPERAZINE HYDROBROMIDE GSSG 1of4 Acetaminophen glutathion Glycine, N-(S-(5-(acetylamino)-2-hydroxyphenyl)-N-L-gamma-glutamyl-L-cysteinyl)- N-(S-(5-(Acetylamino)-2-hydroxyphenyl)-N-L-gamma-glutamyl-L-cysteinylglycine Glutathione-S-acetaminophen conjugate 3-(glutathion-S-yl)acetaminophen Acetaminophen glutathione conjugate L-Glu-S-[2-Hydroxy-5-(acetylamino)phenyl]-L-Cys-Gly-OH N-[N-L--Glutamyl-S-[2-hydroxy-5-(acetylamino)phenyl]-L-cysteinyl]glycine Glu-S-(5-Acetylamino-2-hydroxyphenyl)-L-Cys-Gly-OH Glu-S-[2-Hydroxy-5-(acetylamino)phenyl]-Cys-Gly-OH 3-Gsh-acetaminophen Aa-glutathion Aa-gsh 3-(Glutathion-S-yl)acetaMinophen DisodiuM Salt 3-GlutathionylacetaMinophen DisodiuM AcetaMinophen-glutathione Adduct DisodiuM L--GlutaMyl-S-[5-(acetylaMino)-2-hydroxyphenyl]-L-cysteinylglycine DisodiuM Salt Acetaminophen Glutathione Disodium Salt Glutathione Acetaminophen Disodium Salt Glycine, L--glutamyl-S-[5-(acetylamino)-2-hydroxyphenyl]-L-cysteinyl- Acetaminophen Impurity 37 64889-81-2 C18H24N4O8S Amino Acids & Derivatives Intermediates & Fine Chemicals Metabolites & Impurities Pharmaceuticals Sulfur & Selenium Compounds

Increased pro-inflammatory genera (e.g., Enterobacteriaceae )
Gallbladder-related adverse events, including cholelithiasis and cholecystitis, have been reported more frequently in patients receiving semaglutide compared to placebo in clinical trials, with an incidence of approximately two to three percent
B7-H3 targeted CAR-T cells locally suppressed tumor progression without serious side effects which indicated the tolerability, safety and efficacy of the therapy
Research commonly explores its connection to